<DOC>
	<DOCNO>NCT02666248</DOCNO>
	<brief_summary>This non-therapeutic , long-term follow-up ( LTFU ) study subject receive retroviral-based gene therapy product cancer study . All subject LTFU protocol receive lentiviral modify T cell engineer express anti-EGFRvIII scFv Chimeric Antigen Receptor ( CAR ) .</brief_summary>
	<brief_title>Long-term Follow-up Subjects Exposed Lentiviral-based CART-EGFRvIII Gene-modified Cellular Therapy Products Cancer Studies</brief_title>
	<detailed_description>The primary objective study monitor adult subject , participant clinical trial , receive T cell modify lentiviral vector encode chimeric antigen receptor specific EGFRvIII , adverse event may associate lentiviral vector gene transfer insertional oncogenesis .</detailed_description>
	<criteria>Subjects enrol destination protocol receive CARTEGFRvIII cell genetically modify lentiviral vector . All subject participate lentiviral vector study IND 15968 receive CARTEGFRvIII cell ask participate protocol . Subjects 18 year age old Subjects provide informed consent prior study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>